IMFINZI (durvalumab)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·BILIARY TRACT MALIGNANCY·+10
AstraZeneca Pharmaceuticals
Indication
Gastroesophageal junction adenocarcinoma
Gastroesophageal junction adenocarcinoma is a malignant epithelial neoplasm arising at the anatomic transition zone between the distal esophagus and the proximal stomach. Read more about Gastroesophageal junction adenocarcinoma
1 drugs 1 manufacturers
Drugs that treat it
Common Gastroesophageal junction adenocarcinoma therapies.
Filter & compare in the drug finder →Opens the drug finder with Gastroesophageal junction adenocarcinoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonGastroesophageal junction adenocarcinoma is a malignant epithelial neoplasm arising at the anatomic transition zone between the distal esophagus and the proximal stomach.
Primarily affecting the upper gastrointestinal tract—most commonly older adults and males—it is strongly associated with chronic gastroesophageal reflux disease, obesity, and specialized intestinal metaplasia known as Barrett esophagus.
Pathophysiologically, persistent acid and bile exposure induces chronic mucosal inflammation and genomic alterations, driving neoplastic transformation of glandular epithelium.
Clinically, it typically presents with progressive dysphagia, unintentional weight loss, early satiety, epigastric pain, or occult gastrointestinal bleeding, and it carries a marked propensity for transmural invasion and regional lymph node metastasis.
- nih.gov
Gastroesophageal junction adenocarcinoma is a malignant epithelial neoplasm arising at the anatomic transition zone between the distal esophagus and the proximal stomach Primarily affecting the upper gastrointestinal tract—most commonly older adults and males—it is strongly associated with chronic gastroesophageal reflux disease, obesity, and specialized intestinal metaplasia known as Barrett esophagus Clinically, it typically presents with progressive dysphagia, unintentional weight loss, early...
- nih.gov
Gastroesophageal junction adenocarcinoma is a malignant epithelial neoplasm arising at the anatomic transition zone between the distal esophagus and the proximal stomach Primarily affecting the upper gastrointestinal tract—most commonly older adults and males—it is strongly associated with chronic gastroesophageal reflux disease, obesity, and specialized intestinal metaplasia known as Barrett esophagus Pathophysiologically, persistent acid and bile exposure induces chronic mucosal inflammation a...
- nih.gov
Clinically, it typically presents with progressive dysphagia, unintentional weight loss, early satiety, epigastric pain, or occult gastrointestinal bleeding, and it carries a marked propensity for transmural invasion and regional lymph node metastasis
Personalize your experience
Follow Gastroesophageal junction adenocarcinoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.